KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 26, 2024, by KALA BIO, Inc., a biopharmaceutical company. The filing details a private placement transaction and the creation of a new class of preferred stock to secure funding for operations.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Common Stock and Series H Convertible Non-Redeemable Preferred Stock.
- Aggregate Gross Proceeds: Approximately $12.5 million.
- Common Stock Issued: 1,197,314 shares at $5.85 per share.
- Preferred Stock Issued: 9,393 shares of Series H Preferred Stock at $585.00 per share.
- Cash Runway: Management estimates that proceeds from this placement, combined with $9.1 million in remaining funding from the California Institute for Regenerative Medicine (CIRM), will fund operations into the fourth quarter of 2025.
- Outstanding Shares: Expected to be 4,458,909 shares of Common Stock immediately following the closing.
Material Changes and Capital Structure
The company entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional investors. A Certificate of Designations was filed for the Series H Preferred Stock, which ranks senior to Common Stock and on parity with Series E, F, and G Preferred Stock. The Series H Preferred Stock is convertible into Common Stock at a rate of 100 shares of Common Stock per share of Preferred Stock, subject to a 9.99% beneficial ownership limitation (adjustable up to 19.99% with notice).
Guidance, Outlook, and Risks
Management anticipates the closing of the private placement on or about June 28, 2024. The company has committed to filing a registration statement for the resale of securities within 30 days of closing. If the registration statement is not filed or declared effective within specified deadlines, the company agreed to pay liquidated damages of 1.0% of the investment amount per 30-day period to certain purchasers.
Forward-looking statements regarding the cash runway and CIRM funding are subject to risks, including the ability to maintain Nasdaq listing compliance, satisfy loan covenants, and achieve clinical milestones. The filing notes that actual results may differ materially from expectations.
Investor Verification Checklist
- Confirm the closing of the private placement and receipt of the $12.5 million in proceeds.
- Verify the filing and effectiveness of the registration statement for the resale of Placement Shares.
- Monitor the status of the $9.1 million CIRM Award funding to ensure the projected cash runway into Q4 2025 remains valid.
- Review the Certificate of Designations for Series H Preferred Stock to understand conversion mechanics and liquidation preferences.
- Assess the impact of the new share issuance on existing shareholder dilution.